Needham & Company LLC Cuts Collegium Pharmaceutical (NASDAQ:COLL) Price Target to $46.00

Key Points

• Needham cut Collegium Pharmaceutical’s price target to $46 from $56 but maintained a “buy” rating, implying roughly 59% upside from the reported $29 share price. Analysts overall hold a “Moderate Buy” consensus with an average target of $55.
• Collegium exceeded quarterly expectations, reporting adjusted EPS of $1.92 versus the $1.72 estimate and revenue of about $199.9 million, up 6.3% year over year.
• Reduced full-year guidance and weakness in the pain portfolio weigh on the outlook: product revenue and adjusted EBITDA forecasts were lowered, while pain revenue fell 9% because of declines in Nucynta and Xtampza ER.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) had its price objective lowered by research analysts at Needham & Company LLC from $56.00 to $46.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the specialty pharmaceutical company's stock. Needham & Company LLC's price objective would indicate a potential upside of 58.59% from the company's current price.

A number of other analysts have also weighed in on COLL. Zacks Research lowered Collegium Pharmaceutical from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, July 28th. Truist Financial raised shares of Collegium Pharmaceutical to a "strong-buy" rating in a report on Monday, June 15th. Wall Street Zen downgraded shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 25th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $55.00.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL traded down $6.74 during trading hours on Thursday, reaching $29.00. 1,366,140 shares of the stock traded hands, compared to its average volume of 474,402. The company's 50-day simple moving average is $34.95 and its two-hundred day simple moving average is $37.24. The company has a market capitalization of $940.75 million, a P/E ratio of 14.28 and a beta of 0.73. Collegium Pharmaceutical has a 52-week low of $29.21 and a 52-week high of $50.79. The company has a quick ratio of 1.62, a current ratio of 1.71 and a debt-to-equity ratio of 2.47.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The specialty pharmaceutical company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The firm had revenue of $199.88 million for the quarter, compared to the consensus estimate of $199.62 million. During the same period last year, the firm posted $1.68 earnings per share. The business's revenue was up 6.3% compared to the same quarter last year. Equities research analysts forecast that Collegium Pharmaceutical will post 6.76 EPS for the current year.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of large investors have recently added to or reduced their stakes in COLL. Janus Henderson Group PLC increased its position in shares of Collegium Pharmaceutical by 59.1% during the 4th quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company's stock valued at $67,026,000 after purchasing an additional 538,337 shares during the last quarter. Massachusetts Financial Services Co. MA increased its holdings in Collegium Pharmaceutical by 65.3% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company's stock valued at $60,776,000 after buying an additional 518,721 shares during the last quarter. Millennium Management LLC boosted its stake in shares of Collegium Pharmaceutical by 248.5% during the 1st quarter. Millennium Management LLC now owns 647,832 shares of the specialty pharmaceutical company's stock worth $19,338,000 after acquiring an additional 461,914 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Collegium Pharmaceutical by 897.2% during the 3rd quarter. Two Sigma Investments LP now owns 269,318 shares of the specialty pharmaceutical company's stock valued at $9,423,000 after acquiring an additional 242,310 shares during the period. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Collegium Pharmaceutical in the 2nd quarter worth $8,506,000.

More Collegium Pharmaceutical News

Here are the key news stories impacting Collegium Pharmaceutical this week:

• Positive Sentiment: Q2 adjusted earnings exceeded expectations. Collegium reported adjusted EPS of $1.92, ahead of the $1.72 consensus estimate and up from $1.68 a year earlier. Revenue of $199.9 million also modestly surpassed estimates and increased approximately 6% year over year. Collegium Pharmaceutical Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: ADHD growth and the AZSTARYS acquisition support the long-term outlook. JORNAY PM revenue rose 41% to $46.1 million, while AZSTARYS contributed $12.9 million during its partial quarter following the completed acquisition. Collegium raised its 2026 AZSTARYS revenue outlook to $65 million–$75 million from $60 million–$70 million. Collegium Reports Q2 Results and Completes AZSTARYS Acquisition
• Positive Sentiment: Operating cash flow was strong at $71.3 million, and adjusted EBITDA increased 8% year over year to $113.8 million, providing financial support for integration and future investment.
• Neutral Sentiment: The company reaffirmed its JORNAY PM revenue forecast of $190 million–$200 million, indicating continued confidence in its established ADHD product.
• Negative Sentiment: Full-year guidance was cut below Wall Street expectations. Collegium now expects 2026 product revenue of $825 million–$855 million, down from $865 million–$895 million and below the approximately $872.4 million consensus estimate. Adjusted EBITDA guidance was also reduced to $445 million–$470 million from $475 million–$500 million.
• Negative Sentiment: The pain portfolio remains under pressure. Pain revenue declined 9% year over year to $140.9 million, led by a 24% drop in Nucynta franchise revenue and a 14% decrease in Xtampza ER revenue. Management attributed the guidance reduction largely to lower-than-expected pricing for Nucynta authorized generics.
• Negative Sentiment: GAAP results deteriorated to a $15.1 million net loss from $12.0 million of net income a year earlier, while GAAP operating expenses increased 45%, partly reflecting acquisition-related costs and higher amortization.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company's core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company's principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source